Dashboard
Manage Tickers

GILD


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

cantor-fitzgerald-reiterates-neutral-on-gilead-sciences-maintains-70-price-target
Cantor Fitzgerald Reiterates Neutral on Gi...
09/16/2024 15:47:13

Cantor Fitzgerald analyst Olivia Brayer reiterates Gilead Sciences (NASDAQ:GILD) with a Neutral and maintains $70 price target.

100-invested-in-this-stock-20-years-ago-would-be-worth-900-today
$100 Invested In This Stock 20 Years Ago W...
09/13/2024 16:00:58

marengo-therapeutics-enters-clinical-study-collaboration-and-supply-agreement-with-gilead-sciences
Marengo Therapeutics Enters Clinical Study...
09/13/2024 11:06:14

The collaboration plans to evaluate the combination of Marengo's first-in-class TCR Vβ selective dual T cell agonist, STAR0...

gilead-unveils-remarkable-outcomes-from-late-stage-lenacapavir-study-showing-promise-in-preventing-hiv-infections
Gilead Unveils 'Remarkable Outcomes' From ...
09/12/2024 17:46:36

Gilead Sciences' Phase 3 trial results show twice-yearly HIV-1 capsid inhibitor lenacapavir reduced HIV infections by 96%, ...

what-the-options-market-tells-us-about-gilead-sciences
What the Options Market Tells Us About Gil...
09/12/2024 15:02:49

gilead-announces-results-of-interim-analysis-from-second-phase-3-trial-showing-twice-yearly-lenacapavir-reduced-hiv-infections-by-96
Gilead Announces Results Of Interim Analys...
09/12/2024 12:36:05

piper-sandler-maintains-overweight-on-gilead-sciences-maintains-95-price-target
Piper Sandler Maintains Overweight on Gile...
09/11/2024 13:55:21

Piper Sandler analyst Joseph Catanzaro maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and maintains $95 price tar...

gilead-sciences-and-genesis-therapeutics-announce-strategic-collaboration-to-develop-novel-small-molecule-therapies-gilead-gains-exclusive-rights-to-develop-and-commercialize-products-using-genesiss-gems-ai-platform-for-target-optimization
Gilead Sciences And Genesis Therapeutics A...
09/10/2024 12:04:31

Core News & Articles
AstraZeneca Says Datopotamab Deruxtecan Sh...
09/09/2024 17:55:38

cantor-fitzgerald-reiterates-neutral-on-gilead-sciences-maintains-70-price-target
Cantor Fitzgerald Reiterates Neutral on Gi...
09/09/2024 15:38:20

Cantor Fitzgerald analyst Olivia Brayer reiterates Gilead Sciences (NASDAQ:GILD) with a Neutral and maintains $70 price target.

peering-into-gilead-sciencess-recent-short-interest
Peering Into Gilead Sciences's Recent Shor...
09/06/2024 19:00:21

gilead-to-present-new-trodelvy-data-at-the-iaslc-2024-world-conference-on-lung-cancer
Gilead To Present New Trodelvy Data At The...
09/05/2024 12:12:48

-Data Span Multiple Types of Lung Cancer and Lines of Therapy-Gilead Sciences, Inc. (NASDAQ:GILD) will present new data from th...

unveiling-10-analyst-insights-on-gilead-sciences
Unveiling 10 Analyst Insights On Gilead Sc...
09/04/2024 14:00:45

rbc-capital-maintains-sector-perform-on-gilead-sciences-raises-price-target-to-74
RBC Capital Maintains Sector Perform on Gi...
09/04/2024 13:15:08

RBC Capital analyst Brian Abrahams maintains Gilead Sciences (NASDAQ:GILD) with a Sector Perform and raises the price target...

mercks-death-cross-vs-gileads-golden-cross-pharma-giants-diverge-on-wall-street
Merck's Death Cross Vs. Gilead's Golden Cr...
09/03/2024 20:17:53

Merck flirts with bearish trends; Gilead is on a golden streak. Who wins? Investors should keep an eye on these diverging techn...

gilead-sciences-options-trading-a-deep-dive-into-market-sentiment
Gilead Sciences Options Trading: A Deep Di...
09/03/2024 16:30:32

avenzo-therapeutics-announces-clinical-study-collaboration-with-gilead-sciences-to-evaluate-avzo-021-and-trodelvy-in-hrher2--metastatic-breast-cancer
Avenzo Therapeutics Announces Clinical Stu...
09/03/2024 13:03:49

AVZO-021, a potential best-in-class CDK2 inhibitor, to be evaluated in combination with Trodelvy (sacituzumab govitecan-hziy), ...

decoding-gilead-sciencess-options-activity-whats-the-big-picture
Decoding Gilead Sciences's Options Activit...
08/27/2024 18:00:52

100-invested-in-this-stock-20-years-ago-would-be-worth-900-today
$100 Invested In This Stock 20 Years Ago W...
08/22/2024 16:01:05

peering-into-gilead-sciencess-recent-short-interest
Peering Into Gilead Sciences's Recent Shor...
08/20/2024 16:00:15

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION